A Medical Device Daily
Boston Scientific (Natick, Massachusetts) reported that it has completed the initial launch of its Taxus Libertépaclitaxel-eluting coronary stent system. The company launched the next-generation stent system in 18 countries outside the U.S. in mid-January.
Boston Sci said early physician feedback has been positive, including reaction from physicians doing live cases at the 14th annual Singapore LIVE course.
Maurice Buchbinder, MD, of the Foundation for Cardiovascular Medicine (San Diego), said, “Despite somewhat challenging anatomy, the Taxus Libertéstent system performed very nicely, crossing the lesions with ease and conforming to the anatomy very well. The angiographic results were superb. The Libertéis a significant advance in drug-eluting stent platform technology, which will enhance percutaneous therapy for more complex coronary anatomy.“
Boston Scientific President and CEO Jim Tobin said the company is “pleased that the feedback has been so positive on this next-generation technology.“ He added, “The innovative design of the Libertéstent significantly improves deliverability and conformability, and paclitaxel is well-known for its safety and efficacy. The Libertéstent system is an important advance in the treatment of coronary artery disease.“